No­var­tis un­veils 'US-first' strat­e­gy ahead of San­doz spin­off

Weeks af­ter an­nounc­ing the spin­off of gener­ics arm San­doz, Vas Narasimhan paints a pic­ture of the new, slim­mer No­var­tis — with a “US-first mind­set,” he said at an in­vestor event on Thurs­day.

The CEO un­veiled am­bi­tious plans to be­come a top-five play­er in the US by 2027 at No­var­tis’ “Meet the Man­age­ment” event in Basel, Switzer­land, which means ramp­ing up clin­i­cal tri­als in the states and “build­ing ca­pa­bil­i­ty and tal­ent, among oth­er things.” The com­pa­ny’s al­so shoot­ing for a top-three rank­ing in Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER